Illumina发布NovaSeq X性能升级,包括Q70质量评分 - 临床实验室产品
Illumina Announces NovaSeq X Performance Upgrades Including Q70 Quality Scores - Clinical Lab Products
生物技术与制药领域的最新动态
Illumina Announces NovaSeq X Performance Upgrades Including Q70 Quality Scores - Clinical Lab Products
SPT Labtech to collaborate with Illumina to develop automated platform supporting genomics in decentralized healthcare settings - the-scientist.com
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026 - BioSpace
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026 - Yahoo Finance
SPT Labtech to collaborate with Illumina to develop automated platform supporting genomics in decentralized healthcare settings - News-Medical
How Illumina multiomics helps scientists track elusive ovarian cancers - Stock Titan
Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics - PR Newswire
Illumina Genome Push Raises Questions On Growth, Adoption And Valuation - simplywall.st
Assessing Illumina (ILMN) Valuation After Recent Share Price Rebound And Longer Term Volatility - Yahoo Finance
Illumina launches TruPath Genome, setting a new standard in genomic insight - Investing News Network
Illumina Launches TruPath Genome Workflow Solution - marketscreener.com
Illumina launches TruPath Genome, setting a new standard in genomic insight - Illumina
Illumina's TruPath Genome offers rapid whole genome testing for rare disease - Stock Titan
Illumina launches TruPath Genome, setting a new standard in genomic insight - PR Newswire
NovaSeq X Series innovation roadmap - Illumina
Next Generation Sequencing Market Competitive Landscape Report 2025 Featuring Top Players - Thermo Fisher Scientific, Pacific Biosciences, Illumina, Roche - Yahoo Finance Singapore
Single Cell Multiomics Market Is Going to Boom |• 10x Genomics • Illumina - openPR.com
The Bull Case For Illumina (ILMN) Could Change Following Buybacks And NovaSeq X Roadmap Reveal – Learn Why - simplywall.st
UPDATED: FDA illuminates new approval pathway for bespoke gene editing therapies
Illumina, Inc. (ILMN) Stock Analysis: Exploring a 15.62% Potential Upside in the Genomics Sector - DirectorsTalk Interviews